ArticleBreast cancer research : BCR2025
Genomic landscape of cancer driver genes in Omani breast cancers: a pilot study.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidimensional roles and clinical significance of GATA3 in breast cancer.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe global rise in breast cancer (BC) incidence is mirrored in the Sultanate of Oman, where the median age of diagnosis is strikingly young at 47 years. This pilot study represents the first in the region to examine the genetic alterations of Omani BC biopsies and resected tumors and their correlations with patient characteristics using a targeted pan-cancer panel.
methodsUtilizing the Oncomine Comprehensive Assay Plus, we profiled 40 BC biopsies alongside 22 matched post-neoadjuvant chemotherapy samples, identifying single-nucleotide variations (SNVs) and copy number variations (CNVs). Chi-Square and Fisher's Exact tests were used for categorical variables. In contrast, the Independent T-test and Levene test were used for continuous variables. Comparative analyses were conducted using the METABRIC and TCGA datasets to place these findings in a global context.
resultsThe data revealed molecular patterns between early-onset (under 50 years) and late-onset (50 years and older) cases. Notably, SNVs were predominant in late-onset tumors, while CNVs were more frequent in early-onset cases. PIK3CA SNVs emerged as a hallmark of late-onset BC, which persists across pre- and post-treatment stages. NTRK1 mutations were linked to late-onset cases at pre-treatment, while OR6F1 CNV was exclusive to early-onset tumors. The five genes with the highest CNV prevalence in the cohort were CDK12, ERBB2, BRIP1, and BLM, and they closely mirrored those found in global datasets. Correlations with clinical features identified CHEK2 alterations associated with high-grade tumors and luminal and HER2 type, while TP53 mutations were predominantly found in TNBC cases. Mutations in CBFB and GATA3 were predominantly enriched in luminal subtypes, and TSC1 mutations corresponded with smaller tumors, whereas FGFR4 SNVs were linked to nodal (N) status. Additionally, we identified 19 new SNV variants distributed across seven genes that were not recorded in the public databases.
conclusionThis study sheds light on the genetic landscape of BC driver genes in Oman and the shared molecular traits with Western populations while uncovering unique regional alterations in NTRK1, OR6F1, and FGFR4. These findings highlight the need for region-specific insights to inform targeted therapies and personalized care, advancing the global understanding of BC biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.